UBiGene unveils 4th GMP production base

Nansha district has attracted numerous star companies in the biopharmaceutical industry, including uBiGene, to invest in Nansha. UBiGene officially launched its fourth GMP production base in the Guangdong Medical Valley Nansha Industrial Park on March 22.

UBiGene is a global one-stop Contract Development and Manufacturing Organization (CDMO) service provider for Cell and Gene Therapy (CGT) drugs and has established a global production service network in Boston, US, Jinan, and Suzhou, China.

The settlement of uBiGene has injected new vitality into the growth of the medical industry, attracting talent aggregation and driving technological innovation in Nansha. The authorities in Nansha are committed to creating a favorable environment within the park, providing professional support services, and assisting enterprises in their rapid growth.

The CEO Li Qichen stated, "The Guangzhou base is currently in the trial operation stage, and starting from May, it will provide good manufacturing practice (GMP) for cell therapy products. The new base is located within a half-hour transportation circle of the Guangdong-Hong Kong-Macao Greater Bay Area, with convenient transportation. Moreover, hospitals, research institutes, and innovative pharmaceutical enterprises are highly concentrated, and a good industrial layout can better promote the development of uBiGene."

Nansha biomedicine industrial zone. [Photo/WeChat account: gz_nanshafabu]